Adial Pharmaceuticals, Inc. Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share
Adial Pharmaceuticals, Inc. (ADIL) reported Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share of -$1.32 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare · last filed 2025-03-04
- Adial Pharmaceuticals, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2023-09-30 was -$0.03.
- Adial Pharmaceuticals, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2023-06-30 was $2.30.
- Adial Pharmaceuticals, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2022-09-30 was -$0.54.
- Adial Pharmaceuticals, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2022-06-30 was -$0.63.
- Adial Pharmaceuticals, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2023 was -$1.32.
- Adial Pharmaceuticals, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2022 was -$1.93.
| Period end | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 6 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | -$1.32 10-K · filed 2025-03-04 | $1.32 10-K · filed 2024-04-01 | |||
| 2023-09-30 | -$0.03 10-Q · filed 2024-11-13 | $1.69 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $2.30 10-Q · filed 2024-08-13 | $1.76 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | -$1.93 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$0.54 10-Q · filed 2023-11-14 | -$1.63 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$0.63 10-Q/A · filed 2023-10-30 | -$1.14 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |